Taylor Morrison Home Corporation reports Q2 results on July 22 against an unusual backdrop: the stock is trading as a pending acquisition target, with Berkshire Hathaway's $72.50-per-share bid reshaping how investors interpret every data point heading into the print.
Options traders have turned decisively bullish, and the degree of the shift is striking. The put/call ratio has dropped to 0.32 — nearly 2.5 standard deviations below its 20-day average of 0.47 — making this one of the most call-heavy readings of the past year. The PCR 52-week low is 0.125, so positioning is approaching the lower end of the range but still well above it. That pattern suggests investors are leaning into upside scenarios rather than hedging for downside, consistent with a deal-premium trade. The stock itself has been remarkably steady given broader homebuilder weakness: TMHC edged up 0.8% on the week while peers including MTH fell 1.8%, KBH dropped 0.4%, and lost 1.2%.
Short interest tells a story of retreating bears. Bears have cut positions sharply — short interest fell roughly 39% over the past month to 3.3% of the free float, about 3.2 million shares. The lending market is exceptionally loose: availability runs at nearly 3,700% of outstanding short interest, meaning there are roughly 37 shares available to borrow for every one currently shorted. Borrowing costs, at 1.3%, are low in absolute terms, though they tripled in the week ending July 17 — a spike that bears watching but remains well below levels that signal genuine squeeze pressure. The ORTEX short score of 32 places the stock in the lower third of the universe on short-seller conviction.
The analyst community has been cooling on the stock even as the deal provides a ceiling and floor dynamic. Barclays downgraded to Equal-Weight on July 14 while nudging its target to $73 — essentially flagging that the Berkshire bid captures most of the near-term upside. Earlier in June, Raymond James, Wolfe Research, Truist, and RBC all moved to neutral-equivalent ratings. The consensus is now a hold with a mean target of $66.75 — notably below the current price of $72.44, reflecting that the Street is pricing in the $72.50 deal rather than standalone fundamentals. The bull case rests on the deal closing cleanly, given low antitrust risk and Berkshire's financial firepower. Bears point to housing market headwinds, TMHC's West segment concentration, and the absence of a competing bid that might force a bump. The EV/EBITDA multiple has compressed 6.6% over the past 30 days to 9.5x, consistent with a market treating this primarily as a deal-certainty trade rather than a growth story. TMHC's EPS surprise factor score ranks in the 80th percentile, and earnings momentum over 90 days scores in the 77th — so the underlying business has been delivering.
Tomorrow's print is therefore less a test of whether Taylor Morrison can beat estimates and more a referendum on whether any detail — order trends, gross margin guidance, or commentary on deal timing — gives the market reason to price in a wider spread or a narrower one.
See the live data behind this article on ORTEX.
Open TMHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
